In patients with MASH cirrhosis and portal hypertension without varices, belapectin 2 mg/kg did not significantly reduce new varices vs placebo at 18 months (10.1% vs 17.8%, p=0.13); 4 mg/kg had no significant effect.
RCTn = 357
Chalasani et al. Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial